Drug intelligence / Profile preview

MSP3-CRM-Vac4All

Development stage: Phase 2
Lead developer: Vac4All
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

MSP3-CRM-Vac4All is a protein-protein conjugate malaria vaccine candidate developed for the prevention of falciparum malaria, particularly in Africa. The vaccine uses a modified merozoite surface protein 3 (MSP3) as the antigen, conjugated to CRM197 (a non-toxic mutant of diphtheria toxin) and formulated with Alhydrogel as an adjuvant. Its mechanism of action is immunostimulation, aiming to elicit an immune response against *Plasmodium falciparum* by targeting the blood-stage parasite. The developer and primary sponsor is Vac4All, with clinical trials conducted in partnership with Sanofi and African research groups. The vaccine has been evaluated in Phase 1b/2b clinical trials for safety, immunogenicity, and efficacy in both adults and children living in malaria-endemic regions[1][2][3][5].

Other names: MSP3-CRM-Vac4All/Alhydrogel

Targets

MSP3 (Plasmodium falciparum merozoite surface protein 3)

Beyond the preview

Go deeper on MSP3-CRM-Vac4All.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSP3-CRM-Vac4All.

Explore the full profile